Meta, Teladoc, Pinterest, Qualcomm, and others are among the stocks that have made the most significant premarket changes.

 

Meta, Teladoc, Pinterest, Qualcomm, and others are among the stocks that have made the most significant premarket changes. Metaphor — In premarket trade, shares of Facebook's parent company rose more than 16 percent after the internet corporation revealed better-than-expected quarterly results. According to StreetAccount, daily active users, which fell for the first time in the fourth quarter, rebounded a little and surpassed analysts' estimates. Despite a revenue shortfall, the stock rallied. Prior to the announcement, the stock was down 48% year to date.

Teladoc - Teladoc's stock price plummeted 43 percent after the telehealth business issued dismal revenue projections and missed profits expectations. Teladoc reported a loss of $41.58 per share on 

$565.4 million in sales. FactSet polled analysts, who predicted a loss of 60 cents per share and $568.7 million in revenue.

McDonald's — The food chain's stock rose 2% in premarket trade as first-quarter revenue exceeded expectations. According to Refinitiv, McDonald's reported $5.67 billion in first-quarter sales, vs $5.59 billion projected by analysts. Same-store sales increased by 3.5 percent in the United States and considerably more in overseas markets.

Southwest Airlines is a low-cost airline based in Texas. The airline's stock jumped more than 3% in premarket trade after the firm issued an upbeat forecast. Southwest said it projected revenue to increase by 8% to 12% in the second quarter of 2019 compared to the same period the year before, before the pandemic. According to Refinitiv, the corporation lost 32 cents per share in the first quarter, somewhat more than the 30 cents projected by analysts.

PayPal — The payment’s company saw shares rise 3.4% in early trading after it beat revenue estimates for the first quarter and posted a slight increase in payments volume. The stock price got a lift despite issuing weak guidance for the second quarter and full year.

Eli Lilly — The drug maker’s shares gained 3.4% in premarket trading after the company reported results from a clinical trial showing its obesity drug tirzepatide helped patients lose up to 22.5% of their weight. Eli Lilly also reported better-than-expected earnings and revenue for the first quarter and boosted its full-year revenue guidance.